---
title: "Xilio Therapeutics Partners with AbbVie for Immunotherapy Expansion"
date: "2025-02-12 20:59:16"
summary: "Maximize Your Portfolio with Data Driven Insights:Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions. Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart PortfolioThe latest announcement is out from..."
categories:
  - "tipranks_announcements"
lang:
  - "en"
translations:
  - "en"
tags:
  - "tipranks_announcements"
menu: ""
thumbnail: "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_2157214825-750x406.jpg"
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

### Maximize Your Portfolio with Data Driven Insights:

* Leverage the power of [TipRanks' Smart Score](https://www.tipranks.com/screener/top-smart-score-stocks), a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
* Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with  [Your Smart Portfolio](https://www.tipranks.com/smart-portfolio/holdings)

The latest announcement is out from Xilio Therapeutics ( [(XLO)](https://www.tipranks.com/stocks/xlo) ).

On February 10, 2025, Xilio Therapeutics announced a collaboration and option agreement with AbbVie to develop novel tumor-activated immunotherapies. The agreement includes an upfront payment of $52 million and potential contingent payments up to $2.1 billion. AbbVie will leverage its oncology expertise alongside Xilio’s proprietary technology to advance masked T cell engagers and other immunotherapies. This collaboration positions Xilio to accelerate its technology’s expansion into next-generation therapies, potentially enhancing its market presence and providing significant financial benefits.

**More about Xilio Therapeutics**

Xilio Therapeutics is a clinical-stage biotechnology company specializing in tumor-activated immuno-oncology therapies. The company aims to improve cancer treatment outcomes by localizing anti-tumor activity within the tumor microenvironment, thereby reducing systemic side effects.

**YTD Price Performance:** -38.60%

**Average Trading Volume:** 490,937

**Technical Sentiment Consensus Rating:** Buy

**Current Market Cap:** $30.66M

For an in-depth examination of XLO stock, go to [TipRanks’ Stock Analysis page](https://www.tipranks.com/stocks/xlo/stock-analysis).

Trending Articles:
------------------

* [SUI Lawsuit Alert! Class Action Against Sun Communities, Inc.](https://www.tipranks.com/news/sui-lawsuit-alert-class-action-against-sun-communities-inc)
* [Meta Stock Alert! Wins New Street-High Price Target from Tigress Financial](https://www.tipranks.com/news/meta-stock-alert-wins-new-street-high-price-target-from-tigress-financial)
* [Buffett’s Berkshire Ups Occidental Stake to 28.3% by Buying More Shares](https://www.tipranks.com/news/buffetts-berkshire-ups-occidental-stake-to-28-3-by-buying-more-shares)

[tipranks_announcements](https://www.tipranks.com/news/company-announcements/xilio-therapeutics-partners-with-abbvie-for-immunotherapy-expansion)
